
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Null Results in Brief |
AIDS and Sexually Transmited Diseases Unit, Laboratorio di Epidemiologia e Biostatistica, Istituto Superiore di Sanità, Rome [G. R., M. G., M. B.], and Laboratory of Virology [A. G., G. C., A. B.] and Centro di Riferimento AIDS e Servizio di Epidemiologia delle Malattie Infettive [D. S., G. I.], Ospedale Forlanini, Rome [G. M.] Istituto Ricovero Cura a Carattere Scientifico (IRCCS) L. Spallanzani, Rome, Italy
| Introduction |
|---|
|
|
|---|
In the present study, we tested the hypothesis that polymorphism at the codon 72 of the p53 is associated with HPV-related SILs of the cervix, studying both HPV-positive and HPV-negative women with or at risk for HIV infection.
| Materials and Methods |
|---|
|
|
|---|
Analysis of Codon-72 Polymorphism.
To analyze the codon-72 polymorphism of p53, a 199-bp product from PCR was digested using restriction and separation procedures described by Ara et al. (9)
.
Statistical Analysis.
The Fishers exact test was used to compare the different proportions of p53 genotypes across the cytological diagnoses. The association between the arginine/arginine allele and SIL after adjustment for other factors was assessed by means of unconditional MLR analysis to compute ORs and 95% CIs.
Results
Two-hundred and forty three Caucasian women (median age, 30 years; range, 1745 years) were included in the study. SIL was diagnosed in 71 (29.2%) of these women: 45 (18.5%) had LSIL, and 26 (10.7%) had HSIL.
HPV-DNA was detected in 80 (32.9%) of 243 women; 130 of 243 women (53.5%) were HIV-positive. HPV typing was performed for 45 of the 80 women with HPV-DNA; 33 (73.3%) of them had high-risk HPV types (i.e., 16, 18, and 31).
The Distribution of the p53 genotype according to cytological findings is presented in Table 1
. Half of the women were found to be homozygous for the arginine allele (Arg/Arg); 39.5% were heterozygous (Arg/Pro); and 11% were homozygous for the proline allele (Pro/Pro). No statistically significant differences were found in the proportions of the different p53 genotypes when comparing the cytological findings (Table 1)
.
|
When the analysis was restricted to the 17 women with high-risk HPV types, the risk of HSIL for women with arginine homozygosis was 2.1 times higher; however, the increase was not statistically significant (95% CI, 0.317.6; data not shown in table
).
Discussion
The findings of our study show no association between arginine homozygosis and SIL, and thus they do not support the hypothesis that the p53 polymorphism is associated with an increased risk of cervical lesions. In particular, we assessed the role of p53 polymorphism, taking into account HPV and HIV infections, which are well-established determinants of SIL (8)
, and found that the presence of such infections does not modify the association between p53 polymorphism and the risk of SIL.
Because we did not study women with invasive cervical cancer, we cannot exclude that the p53 polymorphism may act at later stages of carcinogenesis. For this reason, the findings of this study only suggest that the p53 polymorphism has no effect on the development of preinvasive lesions. Interestingly, we found a lack of an association in both HIV-positive and HIV-negative women, stressing that the effect of HIV-induced immunosuppression is not likely to be modified according to p53 polymorphism.
When the analysis was restricted to women for whom it was possible to evaluate the HPV type, the power of the study to detect a statistically significant association was limited. In fact, we based our sample-size calculation on a relative risk of
7, as suggested by previous studies (3)
.
In conclusion, our study supports the results of previous investigations indicating that p53 polymorphism does not greatly affect the risk of preneoplastic lesions of the cervix and shows that this finding is not modified by concurrent HIV infection.
| Acknowledgments |
|---|
| Footnotes |
|---|
1 Supported by Ricerca Corrente 1998, IRCCS L. Spallanzani, and by Progetto Ricerca AIDS, Ministero della Sanità, Istituto Superiore di Sanità. ![]()
2 To whom requests for reprints should be addressed, at Reparto AIDS e Malattie Sessualmente Trasmesse, Istituto Superiore Sanità, Viale Regina Elena, 299, 00161 Rome, Italy. Phone: 39-06-4938-7209 or 39-06-4938-7211; Fax: 39-06-4938-7210; E-mail: g.rezza{at}iss.it ![]()
3 Members of the DIANAIDS Collaborative Study Group are: B. Suligoi and P. Pezzotti (Istituto Superiore di Sanità, Rome, Italy); A. Sinicco and R. Volante (Amedeo di Savoia and S. Anna, Torino, Italy); I. Errante and G. C. Cecchini (Ospedale Niguarda, Milano, Italy); T. Quirino and A. Agarossi (Ospedale Sacco, Milano, Italy); A. Bergamasco and M. Lomini (Ospedali Civili, Brescia, Italy); E. Vaccher and F. Sopracordevole (CRO, Aviano, Italy); R. Visonà and R. Leveni (Ospedale S. Anna, Como, Italy); L. Sinigolfi and V. Segala (Ospedale S. Anna, Ferrara, Italy); A. Schiesari and A. Boschini (S. Patrignano, Rimini, Italy); M. Pozzi and A. Di Carlo (Ospedale S. Gallicano, Roma, Italy); F. Montella and R. Soraci (Ospedale S. Giovanni, Roma, Italy); G. Liuzzi and M. Sansone (II Policlinico, Naples, Italy); M. Gargiulo (Ospedale Cotugno, Naples, Italy); P. Congedo and C. Carriero (Policlinico, Bari, Italy); and C. DUbaldo, C. Carvelli, and G. Lirosi (L. Spallanzani Hospital, Rome, Italy). ![]()
4 The abbreviations used are: HPV, human papillomavirus; SIL, squamous intraepithelial lesion, MLR, multiple logistic regression; OR, odds ratio; CI, confidence interval; LSIL, low-grade SIL; HSIL, high-grade SIL. ![]()
Received 9/29/00; revised 12/14/00; accepted 2/ 9/01.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A. Koushik, R. W. Platt, and E. L. Franco p53 Codon 72 Polymorphism and Cervical Neoplasia: A Meta-Analysis Review Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 11 - 22. [Abstract] [Full Text] [PDF] |
||||
![]() |
F X Bosch, A Lorincz, N Munoz, C J L M Meijer, and K V Shah The causal relation between human papillomavirus and cervical cancer J. Clin. Pathol., April 1, 2002; 55(4): 244 - 265. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |